

Terms & Conditions



Life Sciences / Biotech Fund

Contact Details

Fund Manager	Privium Fund Management B.V.
Address	Gustav Mahlerplein 3, 1082 MS Amsterdam, the Netherlands
Portfolio Manager	Patrick Krol
Address	Science Park 406, 1098 XH, Amsterdam, the Netherlands
Telephone	+ 31 (20) 579 20 40, Mobile: +31 6 15 07 14 15
Website	www.aescap.com
E-mail	pkrol@aescap.com

Fund Characteristics

Legal status	mutual open-end fund (common Dutch FGR structure)
Fiscal status	100% tax transparent
Minimum investment	500.000 euro
Management fee	0,125% per month (1,5% per year)
Performance fee	20%, fair full historic high watermark (no double dipping)
Subscription	Bi-monthly (twice per month), 1 business day prior transaction day
Redemption	Twice per month, 20 trading days before transaction day
Subscription fee	1%
Redemption fee	0.2%, plus 2% early redemption fee in first three years
Transaction day	the 1st and the 15th of each calendar month or, if such day is not a Business Day, the following Business Day.
Valuation day	the last Business Day prior to a Transaction Day.

Third Parties Involved

Administrator	SGG Financial Services B.V., Hoogoorddreef 15, Amsterdam
Depository	Darwin Depository Services B.V.
Director Depository	SGG Custody B.V., Hoogoorddreef 15, 1101 BA, Amsterdam
Custodian	Binck Bank N.V., Barbara Strozziilaan 301, 1083HN, Amsterdam
Accountant	Mazars, Rotterdam

Bank Details

Accountholder	Stichting Aescap 2.0
Bank	ABN-AMRO Amsterdam
IBAN	NL51ABNA0494667826
BIC/SWIFT	ABNANL2A

Fact Sheet

Life Sciences / Biotech Fund



Strategy

Aescap 2.0, a long-only investor in public life sciences / biotechnology companies, seeks to generate a preferred return over the Nasdaq Biotech Index (NBI) and large biotech funds (500 million Euro+). The outperformance it is aiming at is generated by investing in a focused manner, around 18 holdings at a time. Portfolio selections are based on a high conviction, fueled by fundamental analyses and an intense dialog with management and relevant experts. The fund does not work with derivatives nor does it use any leverage (other than a maximum of 10% leverage for up to maximum one month to serve switches from one investment to the other).

Focus

Within the focused portfolio of around 18 companies, mainly companies that develop and exploit new innovative medicine, it diversifies over different disease areas, development phases and geographies.

Performance goal

The fund aims to generate an annual average net IRR of 20%+ over the mid-term (4-5 years)

Currencies

The fund is a euro based fund and invests mainly in companies which are traded in euros and dollars. It does not hedge any investments in foreign currencies against the euro. Most life sciences companies are sincere global players and have their income in several currencies which limits the potential risk of the volatility of a currency.

Geographies

The vast majority of the portfolio companies have their headquarters and/or listing in Europe or the US.

Dividend

The dividend the fund receives will be reinvested.

Disclaimer

Privium Fund Management B.V. (Privium) is authorised and regulated by the Dutch Authority for the Financial Markets (www.afm.nl) as an Alternative Investment Fund Manager (AIFM). Both Privium as well as the Fund are included in the register of the AFM. This communication is neither an offer to sell nor a solicitation to invest. Past performance is not indicative of future results. The value of investments and any income generated may go down as well as up and is not guaranteed. For more information, please refer to the Key Information Document or 'KID' and the Prospectus on the website of the fund (www.aescap.com).

The information does not constitute any recommendation, investment proposal, offer to provide a service, solicitation to buy or sell any security or other investment product. The information may be subject to restrictions imposed by law in some jurisdictions. This information is not meant for visitors within a jurisdiction in which such an offer or solicitation is against the law, or to a person to whom it is unlawful to make such offer or solicitation. Privium accepts no liability for infringement of such restrictions. The recipient shall not distribute, forward or publish the information. No rights may be derived from the provided information, data and calculations.

The value of the investments may fluctuate. Past performance is not necessarily a guide to future performance. The value of the products is (among others) subordinated to the developments on financial markets and, if applicable, other markets.

Disclosures for Swiss investors

The Fund has appointed Hugo Fund Services SA, 6 Cours de Rive, 1204 Geneva, Switzerland, as its Swiss Representative. Banque Heritage SA, 61 Route de Chêne, CH-1207 Geneva, Switzerland is the Swiss Paying Agent. In Switzerland Aescap2.0 shall be distributed exclusively to qualified investors. The fund offering documents and audited financial statements can be obtained free of charge from the Representative. The place of performance with respect to Aescap2.0 distributed in or from Switzerland is the registered office of the Representative.